Details of the Drug Combinations

General Information of This Drug (ID: DM6LDI4)

Drug Name

BMS-986158 DM6LDI4

Synonyms

KGERZPVQIRYWRK-GDLZYMKVSA-N; 1800340-40-2; UNII-X8BW0MQ5PI; X8BW0MQ5PI; SCHEMBL16861831; EX-A2678; CS-7497; HY-101567; (S)-2-(3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-5H-pyrido[3,2-b]indol-7-yl)propan-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Fedratinib + BMS-986158	DCYEMJG	Fedratinib	Myelofibrosis	[2]
Ruxolitinib + BMS-986158	DCCMQAQ	Ruxolitinib	Myelofibrosis	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02419417) Study of BMS-986158 in Subjects With Select Advanced Cancers (BET). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04817007) A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)